RxSight reports preliminary Q4 revenue $40.2M, consensus $40.39M

Reports preliminary FY24 revenue $139.9M, consensus $140.08M. Preliminary unaudited cash, cash equivalents and short-term investments as of December 31, 2024, is expected to be $237.2M. “During the fourth quarter, we achieved record highs for LDD sales and LAL procedures, meaningfully exceeding our initial full-year 2024 revenue guidance. With nearly one thousand LDDs installed, we now serve an estimated 15% of cataract surgeons in North America, while LAL procedures account for over 10% of the region’s premium IOL market. We believe this sustained growth in one of ophthalmology’s most competitive segments reflects the growing recognition of the superior visual outcomes enabled by adjustability,” said Ron Kurtz, Chief Executive Officer and President of RxSight (RXST).